Lymphatic Malformation
18
9
9
6
Key Insights
Highlights
Success Rate
86% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
5.6%
1 terminated out of 18 trials
85.7%
-0.8% vs benchmark
6%
1 trials in Phase 3/4
0%
0 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (18)
Intralesional Bleomycin Sclerotherapy for Low-Flow Vascular Malformations of the Head and Neck
Efficacy of Rapamycin in the Treatment of Cervico-facial Lymphatic Malformations
Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of Age
A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations
Lymphatic Anomalies Registry for the Assessment of Outcome Data
Weekly Sirolimus Therapy
National Evaluation of Patients With PIK3CA-Related Overgrowth Spectrum (PROS)
A Prospective Study on the Treatment of cLM Based on ICG Imaging
Topical Sirolimus in Cutaneous Lymphatic Malformations
Diagnostic Imaging of Vascular Malformations Using MSOT and ULM
Institution of an Italian Registry and Biobank for Biological Sample Collection
Indocyanine Green Lymphography in Management of Lingual Lymphatic Malformation
Different Doses of Sirolimus for the Treatment of Cystic Lymphatic Malformations
Use of Bleomycin in the Sclerotherapy of Lymphatic Malformations for Pediatric Patients
Clinical Characteristics of Lymphatic Malformations
First in Human Trial of Topical VT30 in Pts With Venous/Lymphatic Malformations Assoc With PIK3CA or TEK Gene Mutations
Vascular Anomaly Pathology and Genomics Biopsy Study
A Pharmacokinetic, Pharmacodynamic, Safety and Tolerability Study of CERC-006 in Adults With Complex Lymphatic Malformations